Resources

Products
- For Providers
- For Life Sciences
Platform
Resources
Company
Press
- Media InsightRX in the news — digital, print, podcasts, and other outlets
- Press Releases Announcements for events, partnerships, and company updates

FEATURED POST

InsightRX Achieves 96.1 Performance Score in KLAS Spotlight as the First Precision Dosing AI Solution

Home
Resources
Blog

Search Blog section Author Tags

Thought Leadership

Sep 21, 2025

Model-Informed Precision Dosing for Conditioning Regimens: Busulfan, Fludarabine, ATG, and More

Product Innovation

Aug 8, 2025

Improving Vancomycin Dosing in Pediatric Subpopulations (Part II): Guiding Model Selection in Oncology Patients

Thought Leadership

Feb 27, 2024

Artificial Intelligence Drives Industry Response to Project Optimus

Thought Leadership

Oct 12, 2023

Using hybrid PKPD/ML models to accurately predict risk of neutropenia

Thought Leadership

Jul 13, 2022

Project Optimus for Oncology

Product Innovation

Apr 5, 2022

Roadmap Preview: Biomarker-Guided And Pharmacogenomic-Informed Dosing

Maximize therapeutic success with precision medicine.

What We Do

For Providers

Bayesian Dosing (MIPD)
Real-Time Dosing Analytics
Available Drug Modules

For Life Sciences

Precision Dosing in Clinical Trials
PKPD Analytics in Clinical Trials
Companion Applications

How We Do It

Continuous Learning
Integrations
Security & Regulatory
Success & Support
Data Science

Information

Product Innnovation
Scientific Publications
Thought Leadership
White Papers
How to Cite InsightRX

Press

Media
Press Releases

About

Contact Us
Customers
Leadership
Advisory Board
Mission & Vision
Careers

548 Market Street
#88083
San Francisco, CA 94104

View our privacy policy

InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance

FEATURED POST

Model-Informed Precision Dosing for Conditioning Regimens: Busulfan, Fludarabine, ATG, and More

Improving Vancomycin Dosing in Pediatric Subpopulations (Part II): Guiding Model Selection in Oncology Patients

Artificial Intelligence Drives Industry Response to Project Optimus

Using hybrid PKPD/ML models to accurately predict risk of neutropenia

Project Optimus for Oncology

Roadmap Preview: Biomarker-Guided And Pharmacogenomic-Informed Dosing

What We Do

For Providers

For Life Sciences

How We Do It

Information

Resources

Press

About

548 Market Street#88083San Francisco, CA 94104

548 Market Street#88083San Francisco, CA 94104

548 Market Street
#88083
San Francisco, CA 94104

548 Market Street
#88083
San Francisco, CA 94104